MiNK Therapeutics Presents Positive Clinical Data for agenT-797

MiNK Therapeutics announced new clinical and translational data for its off-the-shelf iNKT cell therapy, agenT-797, presented at the American Thoracic Society International Conference 2026 and published in Clinical Immunology Communications. The data describes a sequential immunotherapy regimen with agenT-797 and N-803 in a critically ill patient with unresolving disseminated Coccidioides immitis infection and severe acute respiratory distress syndrome. Key findings included pathogen suppression, immune cell recruitment, reduced inflammation, and activation of tissue repair, supporting the company's ongoing randomized Phase 2 clinical trial for agenT-797 in severe acute lung injury and critical illness.